Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares of the company’s stock, valued at $36,324,409.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Jonathan Sheena also recently made the following trade(s):
- On Thursday, August 15th, Jonathan Sheena sold 12,000 shares of Natera stock. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00.
- On Monday, August 12th, Jonathan Sheena sold 2,700 shares of Natera stock. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00.
- On Monday, July 1st, Jonathan Sheena sold 2,700 shares of Natera stock. The stock was sold at an average price of $108.87, for a total transaction of $293,949.00.
Natera Stock Performance
Shares of Natera stock traded up $0.65 during trading on Friday, hitting $127.78. 2,190,370 shares of the stock were exchanged, compared to its average volume of 1,369,813. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a fifty day moving average price of $114.45 and a 200-day moving average price of $105.31. The stock has a market capitalization of $15.69 billion, a price-to-earnings ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01.
Analysts Set New Price Targets
NTRA has been the subject of a number of research reports. Robert W. Baird increased their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Piper Sandler reiterated an “overweight” rating and set a $150.00 price objective on shares of Natera in a report on Friday, September 13th. BTIG Research boosted their target price on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, August 9th. UBS Group decreased their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $120.07.
Get Our Latest Research Report on NTRA
Institutional Investors Weigh In On Natera
Several hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new stake in Natera during the second quarter worth approximately $28,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter worth approximately $32,000. Quarry LP lifted its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares during the last quarter. GAMMA Investing LLC boosted its stake in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. Finally, YHB Investment Advisors Inc. acquired a new position in Natera in the 1st quarter valued at $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
- Five stocks we like better than Natera
- Breakout Stocks: What They Are and How to Identify Them
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Basic Materials Stocks Investing
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Most Volatile Stocks, What Investors Need to Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.